A new preclinical study published in Biomedicine & Pharmacotherapy found the compound JMV2894 created some modest benefits in a mouse model of severe Duchenne muscular dystrophy (DMD), but more research is needed to learn if the compound has the potential to treat the disease.
JMV2894 is a growth hormone secretagogue (GHS), a type of drug that encourages growth hormone production in the body. GHSs have been shown to limit muscle wasting in animal studies, suggesting their potential as a treatment for DMD.
Read more about DMD prognosis
The study’s authors had previously found that JMV2894 helped prevent the formation of muscle scar tissue in a common mouse model of DMD. To better understand the drug’s impact, in this study the authors tested the treatment on D2-mdx mice, a model that develops more severe DMD-like symptoms. Over six weeks, mice received either a low or high dose of JMV2894 and were observed for changes in muscle function, ultrasound findings and tissue biology.
One of the clearest findings came from observation of the diaphragm, the primary muscle involved in breathing. Mice that received the lower dose of the experimental drug showed a significant improvement in diaphragm movement compared with untreated mice.
In the calf muscles, the higher dose lowered two gene signals related to scarring, but this did not correspond with visible changes in muscle tissue.
Beyond these findings, the drug’s overall impact was modest. Other molecular markers related to scarring and inflammation also declined, but most of these shifts did not produce measurable improvements in muscle composition or function.
Measurements of limb strength, total muscle mass and blood biomarkers of muscle injury remained unchanged. Ultrasound showed slight trends toward higher muscle volume, but these differences were ultimately not significant.
“Overall, our results show that GHSs exert different actions in dystrophic settings, likely related to distinct disease phenotype, reflecting the complexity of translational exercise towards universal therapies in DMD,” the authors wrote.
Instead of pointing to a clear therapeutic effect, the findings suggest that drug responses may differ depending on the underlying genetic features of the disease model. The authors note that understanding these differences is important for guiding future research.
Sign up here to get the latest news, perspectives, and information about DMD sent directly to your inbox. Registration is free and only takes a minute.
